NCT04030260招募中2 期
Regorafenib and PD-1 Antibody in Combination With Radiotherapy With or Without SBRT in Patients With pMMR/MSS and Previously Treated Metastatic Colorectal Cancer
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2019年7月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- The progression-free survival (PFS) rates at 6 months
研究概览
简要总结
REGONIVO is a Phase Ib study to explore the efficacy and safety of regorafenib in combination with nivolumab in the treatment of gastric cancer and colorectal cancer with MSS. The study enrolled 50 patients with advanced disease, including 25 cases of gastric cancer, 25 cases of colorectal cancer, except for one case of colorectal cancer with MSI-H, and others were MSS type. The results of the study showed that patients with colorectal cancer had an objective response rate (ORR) of 36% and a progression-free survival (PFS) of 6.3 months.
Based on the preliminary results of the REGONIVO study, the aim of this phase 2 study is to explore the safety and efficacy of regorafenib and PD-1 antibody with or without radiotherapy in previously treated metastatic colorectal cancer patients with pMMR/MSS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded.
- •Subjects with metastatic colorectal cancer(CRC) (Stage IV).
- •Subjects must have failed at least two lines of prior treatment.
- •Tumor tissues were identified as mismatch repair-proficient (pMMR) by immunohistochemistry (IHC) method or microsatellite stability (MSS) by polymerase chain reaction (PCR).
- •Progression during or within 3 months following the last administration of approved standard therapies which must include a fluoropyrimidine, oxaliplatin and irinotecan.
- •Subjects treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy.
- •Subjects who progress more than 6 months after completion of oxaliplatin containing adjuvant treatment must be retreated with oxaliplatin-based therapy to be eligible.
- •Subjects who have withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease will also be allowed into the study.
- •Subjects may have received prior treatment with Avastin (bevacizumab) and/or Erbitux (cetuximab)/Vectibix (panitumumab) (if KRAS WT)
- •Metastatic CRC subjects must have measurable or non measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of
- •Life expectancy of at least 3 months.
- •Adequate bone marrow, liver and renal function as assessed by the laboratory required by protocol.
排除标准
- •Prior treatment with Regorafenib.
- •Previously received anti-programmed death-1 (PD-1) or its ligand (PD-L1) antibody, anti-cytotoxic T lymphocyte-associated antigen 4 (cytotoxic T-lymphocyte-associated Protein 4, CTLA-4) antibody or other drug/antibody that acts on T cell costimulation or checkpoint pathways.
- •Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
- •Extended field radiotherapy within 4 weeks or limited field radiotherapy within 2 weeks prior to randomization.
- •Cardiological disease including Congestive heart failure, Unstable angina, Myocardial infarction, Cardiac arrhythmias requiring anti-arrhythmic therapy.
- •Uncontrolled hypertension. (Systolic blood pressure 150 mmHg or diastolic pressure 90 mmHg despite optimal medical management).
- •Pleural effusion or ascites that causes respiratory compromise.
- •Arterial or venous thrombotic or embolic events.
- •Any history of or currently known brain metastases.
- •Interstitial lung disease with ongoing signs and symptoms at the time of informed consent.
- •Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 4 week.
研究组 & 干预措施
Regorafenib and PD-1 antibody in Combination with Radiotherapy
Experimental
干预措施: Regorafenib and PD-1 antibody in Combination with Radiotherapy (Drug)
Regorafenib and PD-1 antibody in Combination with Radiotherapy
Experimental
干预措施: Radiation therapy (Radiation)
结局指标
主要结局
The progression-free survival (PFS) rates at 6 months
时间窗: 2 year
The PFS is defined as the time from the start of treatment to the date of first documented PD or death as a result of any cause, whichever occurred first. When a patient was alive and without progression, PFS was censored at the date of the last disease assessment. The PFS rates at 6 months was estimated from Kaplan-Meier curves.
次要结局
- Disease Control Rate (DCR)(2 year)
- The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR).(2 year)
- Overall Survival (OS)(2 year)
- Safety variables will be summarized using descriptive statistics based on adverse events collection(2 year)
研究者
Yanhong Deng
Director of Medical Oncology, Clinical Professor
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal CancerImmunotherapyColorectal CancerNCT04110093Shanghai Changzheng Hospital120
招募中
2 期
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular CarcinomaRegorafenibPD-1 InhibitorHepatocellular CarcinomaNCT05048017Peking Union Medical College Hospital20
已完成
1 期
Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal CancerMetastatic Colorectal CancerNCT03081494Novartis Pharmaceuticals10
已完成
1 期
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerAdvanced Colon AdenocarcinomaMetastatic Colon AdenocarcinomaMetastatic Colorectal AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal AdenocarcinomaStage III Colon Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIA Colon Cancer AJCC v8Stage IIIA Rectal Cancer AJCC v8Stage IIIB Colon Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8Stage IIIC Colon Cancer AJCC v8Stage IIIC Rectal Cancer AJCC v8Stage IV Colon Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IV Rectal Cancer AJCC v8Stage IVA Colon Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVA Rectal Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVB Rectal Cancer AJCC v8Stage IVC Colon Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Stage IVC Rectal Cancer AJCC v8NCT04362839City of Hope Medical Center39
已完成
2 期
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)Colorectal CancerNCT04126733Bayer70